Literature DB >> 27044556

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

David M Livermore1, Shazad Mushtaq2, Marina Warner2, Neil Woodford2.   

Abstract

Eravacycline and comparators were tested against carbapenem- and tigecycline-resistant Enterobacteriaceae and Acinetobacter isolates received at the United Kingdom's national reference laboratory. Eravacycline MICs correlated closely with those of tigecycline but mostly were around 2-fold lower; both molecules retained full activity against isolates with high-level tetracycline and minocycline resistance. MIC90s of eravacycline and tigecycline were raised ca. 2-fold for carbapenem-resistant Enterobacteriaceae compared with carbapenem-susceptible controls, probably reflecting subsets of isolates with increased efflux.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27044556      PMCID： PMC4879382          DOI： 10.1128/AAC.00436-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

2.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Authors:  D M Livermore; S Mushtaq; M Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

3.  A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1991-06       Impact factor: 5.790

Review 4.  Efficacy and safety of tigecycline: a systematic review and meta-analysis.

Authors:  Dafna Yahav; Adi Lador; Mical Paul; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2011-06-18       Impact factor: 5.790

Review 5.  Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.

Authors:  Efthimia Tasina; Anna-Bettina Haidich; Stamatia Kokkali; Malamatenia Arvanitidou
Journal:  Lancet Infect Dis       Date:  2011-07-23       Impact factor: 25.071

6.  Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

Authors:  Kevin P Connors; Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Susan Redican; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

Review 7.  Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs.

Authors:  Fengcai Shen; Qianpeng Han; Di Xie; Ming Fang; Hongke Zeng; Yiyu Deng
Journal:  Int J Infect Dis       Date:  2015-08-15       Impact factor: 3.623

Review 8.  The emergence of clinical resistance to tigecycline.

Authors:  Yan Sun; Yun Cai; Xu Liu; Nan Bai; Beibei Liang; Rui Wang
Journal:  Int J Antimicrob Agents       Date:  2012-11-03       Impact factor: 5.283

Review 9.  Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.

Authors:  Grace C Lee; David S Burgess
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-12-13       Impact factor: 3.944

10.  Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.

Authors:  Fang He; Ying Fu; Qiong Chen; Zhi Ruan; Xiaoting Hua; Hua Zhou; Yunsong Yu
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240
View more
  27 in total

1.  Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.

Authors:  Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 3.  Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).

Authors:  Dana R Bowers; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

4.  Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Bo Bo W Maung; Farehin Khan; Ieva Alisauskaite; Melanie Olesky; Joseph Newman; Abdul Mutlib; Xiaoyun Niu; Michael Satlin; Ravi S Singh; Harmut Derendorf; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 5.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

6.  Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited!

Authors:  Patrick M Honore; Herbert D Spapen
Journal:  Ann Transl Med       Date:  2017-11

7.  New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

Authors:  Troy Kish
Journal:  P T       Date:  2018-02

Review 8.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 9.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

10.  Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.

Authors:  David R Snydman; Laura A McDermott; Nilda V Jacobus; Kathryn Kerstein; Trudy H Grossman; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.